We have recently shown that treatment with bevacizumab can lead to hearing improvement and tumor shrinkage in some NF2 patients with progressive vestibular schwannomas.[9] Tissue analysis of schwannomas suggested activation of the VEGF pathway due to decreased expression of SEMA3, an angiogenesis inhibitor. This evidence concerns the gene NF2 and Vestibular schwannoma.